| Name | Title | Contact Details |
|---|
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Reos Partners (www.reospartners.com) is an international social enterprise that helps people move forward together on their most important and intractable issues. We design, facilitate, and guide processes that enable teams of stakeholders—even those who dont understand or agree with or trust one another—to make progress on their toughest challenges. Our approach is systemic, collaborative, and creative. We partner with governments, corporations, and civil society organizations on challenges such as education, health, food, energy, environment, development, justice, security, and peace. Our work is pragmatic, professional, and tailored to the needs of the specific situation. We operate both globally and locally, with offices in Cambridge (Massachusetts), Geneva, Johannesburg, Melbourne, Montréal, and São Paulo. Our name comes from the Greek "rheos," which means "flow."
The International Center of Photography (ICP) is a prominent institution focused on photography and visual culture, founded in 1974 by photojournalist Cornell Capa. Located in New York Citys Lower East Side, ICP serves as a center for exhibitions, education, and public engagement, highlighting the significance of photography in contemporary society. ICP promotes "concerned photography," which emphasizes socially and politically driven imagery aimed at fostering global change. The center curates rotating exhibitions that showcase both historical and contemporary works, drawing from its extensive archives. It also offers educational programs, serving over 3,000 students annually through various courses and workshops in photography, filmmaking, and visual storytelling. Additionally, ICP engages the public through lectures, symposia, and community events that explore the societal role of photography. ICP targets students, artists, educators, and photography enthusiasts, providing tailored programs for aspiring professionals and lifelong learners. Its mission is to advance photography as a tool for social change and cultural dialogue, solidifying its position as a leader in visual arts education and exhibition.